VanEck Biotech ETF
BBH
83 hedge funds and large institutions have $222M invested in VanEck Biotech ETF in 2017 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 20 increasing their positions, 30 reducing their positions, and 7 closing their positions.
266% more call options, than puts
Call options by funds: $6.67M | Put options by funds: $1.82M
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
19.5% more ownership
Funds ownership: 33.2% → 52.71% (+20%)
5% more funds holding
Funds holding: 79 → 83 (+4)
5% more capital invested
Capital invested by funds: $211M → $222M (+$10.6M)
33% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ZIM
Zacks Investment Management
Chicago,
Illinois
|
+$134M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
+$16.4M |
| 3 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$3.32M |
| 4 |
AL
Aspiriant LLC
Los Angeles,
California
|
+$2.35M |
| 5 |
Morgan Stanley
New York
|
+$1.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$6.94M |
| 2 |
VF
Virtu Financial
New York
|
-$6.06M |
| 3 |
MLL
Moody Lynn & Lieberson
Boston,
Massachusetts
|
-$4.65M |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.47M |
| 5 |
BPC
Banque Pictet & Cie
Geneva 73,
Switzerland
|
-$1.45M |
BBH Hedge Fund Activity: Q2 2017 in Review
83 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q2 2017, worth a combined $222M — up 5% from $211M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new BBH positions and 7 closed out — a net gain of 4 holders — while 20 added to existing stakes and 30 trimmed.
The largest buyer was Zacks Investment Management, opening a new position worth an estimated $134M. The largest seller was Goldman Sachs, cutting an estimated $6.94M.
- 83 institutional investors held VanEck Biotech ETF (BBH) as of Q2 2017, up from 79 in Q1 2017.
- Funds reported $222M of VanEck Biotech ETF stock for Q2 2017, up 5% quarter-over-quarter.
- 11 funds opened new VanEck Biotech ETF positions in Q2 2017 and 7 closed out, a net change of +4 holders.
- The largest VanEck Biotech ETF buyer in Q2 2017 was Zacks Investment Management, an estimated $134M added.
- The largest VanEck Biotech ETF seller in Q2 2017 was Goldman Sachs, an estimated $6.94M sold.
Based on aggregated 13F filings for Q2 2017.